Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

High-Dose Vorinostat With Radiation Therapy in the Treatment of Recurrent Glioma.

Next Previous
Trial Profile

High-Dose Vorinostat With Radiation Therapy in the Treatment of Recurrent Glioma.

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 30 Jul 2015

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vorinostat (Primary)
  • Indications Glioma
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 18 Jan 2013 Planned End Date changed from 31 Jul 2012 to 1 Jul 2016 as reported by ClinicalTrials.gov.
  • 11 Jul 2012 Planned end date changed from 1 Jul 2018 to 31 Jul 2012 as reported by ClinicalTrials.gov record.
  • 11 Jul 2012 Additional lead trial centre, primary endpoints and actual initiation date (Jun 2012) added and planned number of patients changed from 24 to 30 as reported by ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top